Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

Selinexor is the first oral selective inhibitor of nuclear export compound tested for cancer treatment. Selinexor has demonstrated a safety therapy profile with broad antitumor activity against solid and hematological malignancies in phases 2 and 3 clinical trials (#NCT03071276, #NCT02343042, #NCT02...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Machlus, Kellie R., Wu, Stephen K., Vijey, Prakrith, Soussou, Thomas S., Liu, Zhi-Jian, Shacham, Eran, Unger, T. J., Kashyap, Trinayan, Klebanov, Boris, Sola-Visner, Martha, Crochiere, Marsha, Italiano, Joseph E., Landesman, Yosef
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2017
Onderwerpen:
Platelets and Thrombopoiesis
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5580272/
https://ncbi.nlm.nih.gov/pubmed/28630120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-11-752840
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items